BioXcel Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

BioXcel Therapeutics

12/03/2024 13:31

* BioXcel Therapeutics Inc  BTAI.OQ  reported a quarterly
adjusted
loss of 76 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-1.95.  The mean expectation of nine analysts
for the quarter was for a loss of 91 cents per share. Wall
Street expected results to range from $-1.23 to -61 cents per
share.
    * Revenue rose 58% to $376.00 thousand from a year ago;
analysts
expected $711.13 thousand. 
    * BioXcel Therapeutics Inc's reported EPS for the quarter
was a
loss of 76 cents​.
    * The company reported a quarterly loss of $22.26 million.
    * BioXcel Therapeutics Inc shares had fallen by 1.7% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for BioXcel
Therapeutics Inc is $11.50 
This summary was machine generated from LSEG data March 12 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.91          -0.76          Beat
 Sep. 30 2023      -1.30          -1.72          Missed
 Jun. 30 2023      -1.75          -1.83          Missed
 Mar. 31 2023      -1.62          -1.84          Missed